TB remains the world's deadliest infectious disease, killing more people than any other single pathogen.
Tuberculosis has shadowed humanity for millennia, yet it remains the world's deadliest infectious disease — a fact India confronts with particular urgency, bearing nearly a third of the global burden of drug-resistant cases. In response, the Indian Council of Medical Research has launched the TB Research Accelerator Programme, channeling funds toward universities and nonprofits developing faster diagnostics, smarter screening, and new treatments, all oriented toward a national pledge to eliminate TB as a public health threat by 2030. The initiative reflects a hard-won understanding that ambition without new tools is merely hope, and that the distance between a laboratory breakthrough and a patient's recovery must be shortened by design, not chance.
- India recorded nearly 64,000 multidrug-resistant TB cases in 2023 — bacteria that defy standard drugs — representing almost one-third of all such cases worldwide, making inaction a compounding crisis.
- TB mortality in India has declined from 28 to 21 deaths per 100,000 people over the past decade, but the pace of progress falls far short of what the 2030 elimination deadline demands.
- ICMR is deliberately funding only proof-of-concept research — projects already validated enough to move toward clinical deployment — signaling impatience with science that stays in the laboratory.
- Priority areas include AI-powered screening, rapid drug-resistance detection, new anti-TB drug discovery, and nutritional interventions, each targeting a different bottleneck in the current response.
- A recent ICMR study found that shorter treatment regimens for drug-resistant TB simultaneously reduced duration, side effects, mortality, and cost — suggesting that the next generation of tools could transform outcomes on multiple fronts at once.
India's medical research establishment is moving with deliberate urgency. The Indian Council of Medical Research has opened a competitive funding call — the TB Research Accelerator Programme — inviting universities and nonprofits to develop new diagnostics and treatments for tuberculosis, with a clear national target: eliminate the disease as a public health threat by 2030.
The programme is selective by design. ICMR will only fund projects that have already demonstrated proof of concept, technologies mature enough to be validated and scaled into the health system. Priority areas include rapid detection of drug-resistant strains, AI-based screening tools, new anti-TB drug candidates, and evidence-based nutritional support for patients. This is applied research, not exploration.
The stakes are substantial. Tuberculosis remains the world's deadliest infectious disease from a single pathogen, and India carries a disproportionate share of the burden. In 2023, the country recorded nearly 64,000 multidrug-resistant TB cases — close to one-third of the global total. Mortality has fallen, from 28 deaths per 100,000 in 2015 to 21 per 100,000 in 2024, but the trajectory is too slow for the ambition at hand.
India's National TB Elimination Programme has made gains in detection, reporting, and treatment adherence, yet it lacks a robust pipeline of new tools. A recent ICMR study offered a preview of what innovation can achieve: shorter treatment regimens for drug-resistant TB were found to reduce therapy duration, side effects, mortality, and cost simultaneously. The accelerator programme is built on that logic — that well-targeted research can close multiple gaps at once, compressing the distance between discovery and the patients who need it most.
India's medical research establishment is placing a significant bet on speed. The Indian Council of Medical Research has opened a funding call for universities and nonprofits to develop new ways of diagnosing and treating tuberculosis, with a hard deadline: eliminate the disease as a public health threat by 2030. The initiative, called the TB Research Accelerator Programme, will direct money toward institutions working on diagnostic tools, treatment strategies, and other innovations that can move from laboratory to clinic faster than traditional research timelines allow.
The focus areas are specific and urgent. Researchers can pursue rapid detection methods for drug-resistant TB strains, screening approaches powered by artificial intelligence, discovery of new anti-TB drugs, and evidence-based nutritional interventions for patients. But ICMR is not funding blue-sky thinking. The council has made clear it will only support projects that have already demonstrated proof of concept—technologies far enough along that they are ready for validation and eventual scale-up into the health system. This is research with a purpose, not research for its own sake.
The timing reflects a hard reality. Tuberculosis remains the world's deadliest infectious disease, killing more people than any other single pathogen. India carries an outsized share of that burden. In 2023, the country recorded nearly 64,000 cases of multidrug-resistant TB—bacteria that no longer respond to standard first-line drugs. That figure represents almost one-third of all such cases globally. The numbers have improved in one dimension: TB mortality in India fell from 28 deaths per 100,000 people in 2015 to 21 per 100,000 in 2024. Progress, but not enough.
The National TB Elimination Programme, India's coordinated response, has been working to strengthen early detection, case reporting, infection control, and treatment adherence. What it lacks is a pipeline of new tools. Recent research offers a glimmer of what's possible. An ICMR study released months before this funding announcement found that shorter treatment regimens for drug-resistant TB cut the duration of therapy, reduced side effects, lowered mortality, and cost less than conventional approaches. The finding suggests that innovation in this space can deliver on multiple fronts at once—faster recovery, fewer complications, lower expense.
The accelerator programme is designed to close the gap between promising laboratory results and public health deployment. By aligning scientific research directly with national programme priorities, ICMR hopes to compress the timeline from discovery to implementation. The stakes are clear: India cannot reach its 2030 elimination target without new diagnostics that work faster, drugs that work better, and strategies that work cheaper. The research call is an acknowledgment that the tools in hand are not enough.
Notable Quotes
ICMR will only fund projects that have already demonstrated proof of concept—technologies ready for validation and scale-up, not early-stage research.— ICMR funding criteria
The Hearth Conversation Another angle on the story
Why does India need a special accelerator for TB research? Isn't TB research happening already?
It is, but slowly. The gap between a promising lab result and a tool that actually reaches patients can be a decade or more. ICMR is trying to collapse that timeline by funding only projects that are already past the earliest stages—things with proof of concept, ready to be tested and scaled.
And the drug-resistant cases—why are those such a problem?
Because the bacteria have evolved to survive the drugs we've been using for decades. When you have 64,000 cases of that in one country, and that's a third of the world's total, you're looking at a population that standard treatment won't help. You need new drugs, or at least new combinations and regimens.
The mortality numbers actually improved, though. From 28 to 21 per 100,000. Doesn't that suggest things are working?
It does suggest progress. But TB is still the world's deadliest single infectious agent. Progress isn't the same as control. And in a country of 1.4 billion people, even a rate of 21 per 100,000 means tens of thousands of deaths a year.
What's the most promising thing coming out of recent research?
The shorter treatment regimens for drug-resistant TB. They cut the time patients spend on therapy, reduce the side effects that make people stop taking their drugs, and cost less. That's the kind of innovation that could actually change the trajectory—if it can be validated and rolled out.
So this accelerator is betting that more money and faster timelines will produce those kinds of breakthroughs?
Essentially, yes. By removing bureaucratic friction and focusing on projects that are already viable, ICMR is trying to turn research into public health tools before 2030. It's a recognition that the current pace isn't fast enough.